The Latest Breaking News from Lung Cancer

Jackie Carr said her aggressive chemotherapy treatments means she has struggled to muster up the strength to fight the council on something she said should have been sorted out years ago

Unlike breast and prostate cancers there is no national screening program to detect lung cancer, so by the time it's picked up it's often too late.

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ:SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK study in metastatic castrate-resistant prostate cancer (mCRPC).  The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-naïve and abiraterone-progressing…

Here are the main headlines on the Daily Record website today.

Bristol Myers Squibb & Co's (NYSE:BMY) Phase 3 CheckMate -901 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) in urothelial carcinoma did not meet the primary endpoint of overall survival (OS) at the final analysis. The trial compared Opdivo + Yervoy to standard-of-care chemotherapy as a first-line treatment for unresectable or metastatic urothelial carcinoma…

Finger clubbing can be an early sign of the illness

It means people with aggressive lung cancer can see their life expectancy go from two and half to five years

Sufferers might be able to spot a few early symptoms

Lung cancer affects thousands of people and their families across the UK every year.

Lantheus Holdings, Inc. (NASDAQ: LNTH) dosed first patient in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent used to assess PD-L1 expression in cancer cells. NM-01 is being investigated in the Phase 2 PELICAN single-arm trial in non-small cell lung cancer (NSCLC) patients.

A simple finger test can help diagnose lung cancer. Here's the telltale sign on your fingertips that could be an early symptom of lung cancer as well as the first steps of treatment